As long as we are on the OTC the market dictates what the markets dictate albeit a few large holding flippers. Until we up list, only major news changes the dynamics Dave...you need to come to grips with this. Az/pd has many companies attention...Nueroderm, for example, which IS listed on the NASDAQ, has another pd application and an interesting one at that....applied through the skin and into the upper intestines. Clinical Company, but well into their studies...
I don't believe their methodology is superior to MANF in the least. It is too invasive.

http://neuroderm.com/about-neuroderm/

(" ** NEURODERM LTD, $15.03, +10.11 pct

Brokerage Oppenheimer raised its price target to $19 from $18 on the drug developer's stock to reflect higher chances of the company's Parkinson's disease drug being successful in later studies. NeuroDerm on Dec. 30 announced positive mid-stage study data of the drug.)

This is what an uplist can accomplish...this stock is up 12.59% as we speak on mediocre news, the same type of news we've seen AMBS put out routinely but failed to impress "the markets "...

http://ir.neuroderm.com/phoenix.zhtml?c=25374...sharechart

Given time and an uplist, Amarantus will impress all longs imho...